CardioCell
CompanyUnited States
CardioCell LLC develops 2 assets, the furthest in phase 2 (Allogeneic Mesenchymal Bone Marrow Cells in non ischemic heart failure). Mostly cell therapy acting on inflammation and stem cell maintenance; based in the United States.
- Assets
- 2
- Furthest
- Phase 2
- Trials
- 1
- Signals
- 0
Pipeline
2Allogeneic Mesenchymal Bone Marrow Cells
Allogeneic bone marrow-derived mesenchymal stem cells promoting tissue repair and immunomodulation.
Phase 2Cell therapyInflammationnon ischemic heart failure
Umbilical cord-derived mesenchymal stem cells for tissue repair and immunomodulation
Phase 2Cell therapyInflammationStem cell maintenanceCOVID-19 pneumoniaHuntington's disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials1
- Signals2
- Similar companies6
Updated 7 Oct 2026 · 30 sources